Stock-market dispatch — 2026-07-15

Headless run, steps 0.5–7 in-turn. Research output, not advice — brain never trades. Prices are pre-open (EOD = 2026-07-14 close, unchanged from yesterday). Supabase sync is performed by the wrapper, not this run.

Top of mind

Today's yield was breadth, not price — a post-DOGE FDA vein opened in the thinnest vertical (healthcare), and the biggest AI-bull thesis took its first serious first-party punch. The Biotech Hangout ingest produced two genuinely new chains the news cycle hasn't priced: a regulatory right-shift — the FDA took Agios' mitapivat (which missed its sickle-cell endpoint) to priority review with no ADCOM, signalling a materially lower efficacy bar that re-rates left-for-dead rare-disease names (fda-right-shift-to-rare-disease-refile-rerate, AGIO/REPL) — and an ATTR-silencer consolidation after AstraZeneca/Ionis' eplontersen showed no benefit (eplontersen-failure-to-alnylam-silencer-consolidation, long ALNY). Both are low-medium (single-source, Step 3 open) — dispatch-visible, not yet feed-actionable. Meanwhile the AI-capex cluster (still 52% of the book, ⚠ over) drew a first-party bear: Chamath (All-In) put realized enterprise AI ROI at 0–2% with token costs "doubling every ~45 days" and model gains "asymptoted" (ai-roi-reckoning) — balanced, not resolved, by Colas' correction that the real kill-switch is a Fed rate shock, not spender roll-over. Separately, the GS private-credit tension the 07-14 dispatch flagged partially separated in GS's favor (below), and GS enters the trader feed for the first time.

Strongest-conviction buys

Ranked shortlist (4c). Prices 2026-07-14 EOD twelvedata (58/62; ASE/BESI free-tier-403, HXSCL/GNKG OTC-carry). Convictions and prices unchanged vs 07-14 — the delta today is research, not marks.

Watchlist

Undervalued candidates (today)

• MU $983.12 — chain intact (HBM sold out beyond CY2027), ~10× fwd P/E, still −22% from the 52w high. Cleanest dislocation in the book.
• CCJ $91.57 — −32% from high; power-cascade confirmed-grade; the −18.7% live return is ~0% sector-excess (uranium theme sold off, selection intact).
• MP $50.79 — −49% from high; REE breadth-thin leg (live −0.3% sector — same story: theme, not pick).

New chains to investigate (hypothesis-stage)

• rare-endo-vertical-to-neurocrine-vertex — NBIX / VRTX / CRNX. Rare-endocrine vertical roll-up read off the Biotech Hangout panel. Graduate on: a named pipeline asset + a disclosed deal/partnership.
• biogen-tau-failure-to-brain-shuttle-rerate — DNLI / ARWR / BIIB. Tau-failure → brain-shuttle delivery re-rate. Graduate on: a second independent readout supporting the shuttle mechanism.
• semi-revision-exhaustion-to-mag8-rotation — XLK / SMH / XLV / XLF. Earnings-revision breadth exhausting in semis → rotation to healthcare/financials. Graduate on: two consecutive weeks of negative semi revision breadth with positive XLV/XLF.

New theses (now active — dispatch-visible, sub-feed-gate)

• fda-right-shift-to-rare-disease-refile-rerate — AGIO, REPL (lateral QURE/SRPT/RGNX). Post-DOGE FDA accepting endpoint-missing rare-disease programs → PoS re-rates right. Low-medium; Steps 1–2 partial, Step 3 open (the load-bearing risk: a decimated FDA is less predictable, not reliably more lenient).
• eplontersen-failure-to-alnylam-silencer-consolidation — ALNY (constructive BBIO/PFE; negative AZN/IONS). Eplontersen null on tafamidis → ALNY perceived silencer winner (+17%). Step 1 confirmed; the same null threatens ALNY's own adjunctive nucresiran trial (load-bearing risk).
• legal-ai-agents-to-legal-research-incumbent-derate — short/avoid RELX, TRI. Agentic legal AI ($1T market ~4% penetrated) erodes the LexisNexis/Westlaw data-moat; beneficiaries (Legora, Harvey) are private — no public long leg.
• trump-accounts-to-sp500-structural-inflows — SPY/VOO, HOOD. 50–70M auto-created child accounts default into the S&P 500 → persistent price-insensitive bid; HOOD built the rails. Execution-dependent on Treasury/SSA.

Updated theses (existing active)

• ai-financing-supercycle-to-gs-capital-markets-rerate — origination-edge vs late-cycle tension partially separates in GS's favor and GS enters the trader feed (score 0.42). Today's autoresearch: direct-lending defaults are rising (KBRA 2.3%→3.5% TTM, non-accruals +40% seq) but the headline stress is redemption gating (a liquidity-terms event skewing offshore), not defaults — and GS Private Credit Corp's own book took only 3.24% redemptions, fulfilled in full, vs BCRED ~10% / Blue Owl 20–40% gating. Step 3 stays partial (no disclosed GS-book quality number). Strengthened the private-credit hypothesis cluster (bdc-redemption-spiral-to-private-credit-repricing, ai-capex-derate-to-private-credit-contagion, fomc-private-credit-outflows-alt-managers).
• open-source-share-shift-bullish-for-compute — volume/paid-share leg weakened, endpoint held. Sacks (All-In): enterprise open-source paid spend share fell 19%→11% — wallet concentrating to the closed frontier even as token volume rises. Calibration logged; concept stays active (compute benefits regardless of open/closed).

Contradicted / weakened

• AI-capex bull cluster ↔ ai-roi-reckoning (new). Chamath: realized AI ROI 0–2%, token costs doubling ~45 days, gains "asymptoted"; DataTrek: capex spenders (Meta/Oracle) already not rewarded. Balanced by Colas (rate-shock is the real trigger) + Gerstner (TAM). Unresolved tension, not a kill — flagged for a human's eye.
• Open-source paid-share premise — see calibration above (single-metric-premise-contradicted-by-a-different-metric, CALIBRATION).
• THS tradeable dead — TreeHouse Foods taken private (Investindustrial, Feb-2026); the private-label manufacturer leg of consumer-trade-down-to-private-label-manufacturer-treehouse retired → listed beneficiaries shift to off-price (TJX/ROST/BURL) + big-box (WMT/COST).

Open questions worth a human's eye

• Is the AI-capex ROI reckoning a top or a wobble? First-party operator (Chamath) says ROI 0–2% and gains asymptoted; the book is 52% this cluster. The trader's 40% cluster cap already throttles it — but this is the first first-party bear, not a valuation quibble.
• Is medium conviction over-labelled? (5th consecutive mark.) Both live sector-excess < −10% flags (TJX −13.2%, PWR −10.6%) sit in the medium tier again; high/med-high stay positive. Overdue for /reflect-on-me.
• Capital Allocators: 6th consecutive low-novelty ingest (Dambisa Moyo — energy/China reinforcement only). DAILY 0.5 says pause it; the skill can't edit PODCASTS.md — needs a human.

What I looked at

• Run status: headless; steps 0.5–7 in-turn; price fetch paced 8/min to completion, 58/62 + 0 rate errors (api.twelvedata.com reachable — the open network-block risk stays clear).
• Breadth (2a): ai-infrastructure 52% ⚠ over; today's net-new steered to thin healthcare (2 new biotech mechanisms), financials/credit (GS lead/lag autoresearch), consumer (trade-down autoresearch).
• Ingestion veins (0.5–0.7): podcast 10 transcripts (all AssemblyAI-diarized, ~$1.87; diarize budget $9.29/$50 July); earnings 0 (BLK reports today pre-open — transcript not yet published, caught next run; SCHW 07-21; rest deduped); feed quiet (all recent SemiAnalysis/Construction Physics already ingested; only a 07-11 link-roundup, excluded).
• Steps 1–2: 2 autoresearch (private-credit origination lead/lag; consumer trade-down broadening) + 3 buckets (consumer, energy/geopolitics via Iran podcasts, healthcare via Biotech Hangout). 2b prospect-chains: auto-drafted 0 — wiki densely connected (53→57 mechanisms, 60 open hypotheses); candidates duplicated existing hypotheses (healthy signal).
• Sources: 12 promoted (all stock-market), 12 ingested → 17 entities, 3 concepts (ai-roi-reckoning, fda-rare-disease-regulatory-right-shift, us-recession-resistance-regime), 4 mechanisms, 3 hypothesis questions. Zero-novelty: 2 (Dwarkesh/Adam Brown physics; ILtB/John Kim craft).
• Valuation (4b): 11 concept snapshots re-stamped 2026-07-15; prices unchanged (pre-open EOD).
• PAPER-LEDGER weekly mark NOT due (last 07-10, next ~07-17); interim 4e note only.
• Live feedback (4e): performance-latest (22 pos) — 2 flags < −10% sector (TJX, PWR), both medium tier → 0 auto-calibrations. Book-best sector-excess: DNN +14.3%, STVN +9.8%, WST +9.0%.
• Calibrations: 1 (open-source paid-share leg). Conviction buys ranked: 5. New mechanisms: 4. New hypothesis chains: 3.
• Signal feed: full active/armed set, GS added (46 rows) — see step 7 (Supabase sync performed by the wrapper, not this run).